title: Antibody-dependent cellular cytotoxicity in HIV type 1-infected patients receiving VaxSyn, a recombinant gp160 envelope vaccine.
abstract: Antibody-dependent cellular cytotoxicity (ADCC) activity was measured in 60 human immunodeficiency virus (HIV-1)-infected patients receiving a recombinant gp160 (rgp160) envelope protein of HIV-1(NL4-3) in alum and 64 receiving placebo over a 5-year study period. There was no difference in the percentage of ADCC responders when comparing rgp160-immunized patients (mean, 78.4%) with those receiving placebo alone (mean, 81.5%) at any time point examined. Patients were further divided into progression groups regardless of their vaccine status. ADCC activity was somewhat higher in rapid than in slow-progressing groups, although the number that had detectable ADCC activity was equivalent in each group. ADCC activity of sera from rapid- and slow-progressing groups against primary or laboratory isolate envelopes was similar. This study showed that transcription with rgp160 did not appear to enhance HIV-specific ADCC activity. ADCC activity did not appear to correlate with protection against AIDS in this cohort of HIV-1-infected people.
authors.affiliation: The Henry M. Jackson Foundation, Rockville, Maryland 20850, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Cox
authors.forename: R P
authors.initials: RP
authors.lastname: Garner
authors.forename: R R
authors.initials: RR
authors.lastname: Redfield
authors.forename: N E
authors.initials: NE
authors.lastname: Aronson
authors.forename: C
authors.initials: C
authors.lastname: Davis
authors.forename: N
authors.initials: N
authors.lastname: Ruiz
authors.forename: D L
authors.initials: DL
authors.lastname: Birx
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D015331:Cohort Studies; D018450:Disease Progression; D004311:Double-Blind Method; D015483:HIV Antibodies / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000276:immunology*; D015658:HIV Infections / Q000097:blood / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; C082068:HIV-1 IIIB gp120 subunit vaccine; D014614:Vaccines, Synthetic; C053473:VaxSyn HIV-1 (gp160) vaccine